AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12869355
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta‐estradiol orally + 100 mg progesterone daily
Trial: 12869355
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg 17beta‐estradiol transdermally per day + 100 mg progesterone daily
Trial: 12869355
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + 100 mg progesterone daily
Trial: 8249953
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (10 micrograms) at 0, 1, 2, and 11 months of age with hepatitis B immune globulin (0.5 mL/kg) within 2 hours of birth (group A)
Trial: 8249953
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (10 micrograms) at 3, 4, 5, and 11 months of age with hepatitis B immune globulin (0.5 mL/kg) within 2 hours of birth and a second dose at 3 months (group B)
Trial: 27362497
Drug: Standard intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intervention arm (one weekly exercise session for six weeks)
Trial: 24111649
Drug: Glycerin suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin suppository (half every twelve hours) and phototherapy
Trial: 22227086
Drug: Protocol-based weaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-based weaning (PBW) administered by nurses, n = 61
Trial: 15817848
Drug: Medium dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dairy group (calcium intake of approximately 1000-1100 mg/d)
Trial: 15817848
Drug: High dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dairy group (calcium intake of 1300-1400 mg/d)
Trial: 1958561
Drug: TE-300 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TE-300 mg/wk
Trial: 1958561
Drug: ND-300 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND-300 mg/wk
Trial: 1958561
Drug: TE-100 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TE-100 mg/wk
Trial: 6765140
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid and dipyridamol (1,050 mg + 150 mg/day) - group A
Trial: 6765140
Drug: Pentoxifylline (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1,200 mg/day) - group P
Trial: 30704260
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=155)
Trial: 27922936
Drug: TX‐004HR (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX‐004HR (all doses)
Trial: 23444285
Drug: Modified-release prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release prednisone tablets (5 mg) taken at bedtime
Trial: 23444285
Drug: Conventional prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional prednisone (5 mg)
Trial: 23444285
Drug: Modified-release prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release prednisone tablets taken with or after an evening meal
Trial: 23444285
Drug: Modified-release prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release prednisone tablets taken under fasted conditions
Trial: 21833690
Drug: Integrated behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated behavioral and family therapy (IBFT)
Trial: 16930803
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 5 mg cetrorelix acetate
Trial: 16930803
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 10 mg cetrorelix acetate
Trial: 16930803
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg cetrorelix acetate
Trial: 12063916
Drug: Adjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiation therapy
Trial: 782969
Drug: Recombinant WRL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant WRL 105 live attenuated influenza virus vaccine
Trial: 782969
Drug: Neither vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither vaccine nor placebo
Trial: 23546328
Drug: Disinfection with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disinfection with 70% alcohol and 1% iodine solutions
Trial: 19421678
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water soluble contrast agent (Group A)
Trial: 15076943
Drug: Ganciclovir implant
RxNorm normalized name: ganciclovir Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir implant plus oral ganciclovir
Trial: 9396394
Drug: CADO (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CADO (cyclophosphamide 300 mg/m2/d on days 1 to 5, vincristine 1.5 mg/m2/d on days 1 and 5, doxorubicin 60 mg/m2/d on day 5)
Trial: 9396394
Drug: CVP (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVP (cisplatin 40 mg/m2/d and etoposide 100 mg/m2/d on days 1 to 5)
Trial: 9396394
Drug: CADO/CVP (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CADO/CVP (combined treatment)
Trial: 9396394
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of cisplatin
Trial: 3285536
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (low doses of cyclosporine, azathioprine, and steroids)
Trial: 3285536
Drug: Double-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug therapy (higher doses of cyclosporine plus steroids)
Trial: 21877762
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg (DEX group, n=21)
Trial: 16501636
Drug: 10 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg/kg G-CSF for 6 days after percutaneous coronary intervention
Trial: 1510446
Drug: Netilmicin 5
RxNorm normalized name: netilmicin 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin 5 mg/kg once daily
Trial: 1510446
Drug: Netilmicin 2
RxNorm normalized name: netilmicin 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin 2 mg/kg thrice daily
Trial: 6649721
Drug: Running treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running treatment
Trial: 9454384
Drug: Velocity, Intensity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velocity, Intensity, remainder of platelet aggregation induced by ADP 10 mcg/ml, 2.5 mcg/ml, 1.9 mcg/ml
Trial: 8216397
Drug: cM‐T412 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM‐T412 50 mg
Trial: 8216397
Drug: cM‐T412 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM‐T412 100 mg
Trial: 8216397
Drug: cM‐T412 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM‐T412 10 mg
Trial: 3688417
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine anesthesia
Trial: 3688417
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical lidocaine anesthesia (Control)
Trial: 29757876
Drug: Extended carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extended carboplatin infusion (3-hour infusion)
Trial: 29757876
Drug: Standard carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard carboplatin infusion (30-minute infusion)
Trial: 22954201
Drug: Olmesartan/amlodipine (5/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/amlodipine (5/20 mg)
Trial: 21680153
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 400mg once-daily
Trial: 21680153
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 800mg once-daily
Trial: 21680153
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1200mg once-daily
Trial: 31732133
Drug: Physiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy plus conventional treatment
Trial: 26723196
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg daily until delivery
Trial: 24228683
Drug: School hygiene
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School hygiene promotion and water treatment interventions and school sanitation improvements in schools with greater water availability
Trial: 21190603
Drug: Total saponins
RxNorm normalized name: zingiberensis saponin I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total saponins of Panax notoginseng (PNS) extract Xueshuantong 0.45 g once a day for 2 months
Trial: 21190603
Drug: Bailing capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bailing capsule of 1.0 g three times a day for 2 months
Trial: 16823067
Drug: GM-CSF (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (150 microg subcutaneously once daily for 14 days after the second week of radiotherapy)
Trial: 8923073
Drug: 10% low‐molecular‐weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% low‐molecular‐weight HES solution (HES trauma, n = 14; HES sepsis; n = 14)
Trial: 1558306
Drug: Ethanol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.85 g/kg) + Dextroamphetamine (0.09 mg/kg)
Trial: 1558306
Drug: Ethanol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.85 g/kg) + Dextroamphetamine (0.18 mg/kg)
Trial: 1558306
Drug: Ethanol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.85 g/kg) + Placebo Dextroamphetamine
Trial: 1558306
Drug: Placebo Ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ethanol + Dextroamphetamine (0.09 mg/kg)
Trial: 1558306
Drug: Placebo Ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ethanol + Dextroamphetamine (0.18 mg/kg)
Trial: 1558306
Drug: Ethanol +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol + Dextroamphetamine (low-dose)
Trial: 1558306
Drug: Ethanol +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol + Dextroamphetamine (high-dose)
Trial: 2936354
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 mg, 2 times daily)
Trial: 2936354
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg, once daily)
Trial: 25281044
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy using a fixed insulin dosing scheme
Trial: 22721929
Drug: EDTA chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA chelation therapy for 3 months followed by as needed for 24 months
Trial: 22721929
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 months followed by weekly for 5 weeks at 6-month intervals for 24 months
Trial: 24987051
Drug: EDTA chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA chelation therapy
Trial: 16340453
Drug: Alcohol (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.50 g ethanol/kg) drink
Trial: 10525140
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFA) - 600 mg per day for 42 days
Trial: 10525140
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (placebo) - 600 mg per day for 42 days
Trial: 1646291
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan 8 mg
Trial: 31452417
Drug: Midazolam plus
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam plus fentanyl (0.05 mg/kg midazolam + 1.5 μg/kg fentanyl)
Trial: 31452417
Drug: Midazolam plus
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam plus normal saline (0.05 mg/kg midazolam + 0.03 mL/kg normal saline)
Trial: 27736246
Drug: 450 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/d green tea extract (GTE)
Trial: 27736246
Drug: 450 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/d sour tea extract (STE)
Trial: 27736246
Drug: 450 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/d maltodextrin (control)
Trial: 23982033
Drug: β-blockers or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers or renin-angiotensin-aldosterone system blockers
Trial: 21674183
Drug: Quad-helix treatment
RxNorm normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad-helix treatment
Trial: 17552955
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg intravenously every 3 months for four treatments
Trial: 10217590
Drug: Avaxim vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avaxim vaccine (inactivated hepatitis A vaccine), administered in two doses six months apart.
Trial: 7775263
Drug: CPT‐11 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 60 mg/m2
Trial: 7775263
Drug: CPT‐11 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 80 mg/m2 with granulocyte colony-stimulating factor support (2 micrograms/kg x 16 days)
Trial: 2184649
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg, 20 mg, 30 mg
Trial: 28662137
Drug: Moderate-vigorous physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-vigorous physical activity (average daily minutes = 24.0±18.3)
Trial: 28662137
Drug: Sedentary behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedentary behaviour (average daily minutes = 535.2±83.8)
Trial: 28662137
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity frequency (average daily bouts ≥10 min = 0.64±0.74)
Trial: 25909356
Drug: Grazoprevir 100
RxNorm normalized name: grazoprevir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg/elbasvir 50 mg (oral, once-daily for 12 weeks)
Trial: 25909356
Drug: Placebo (deferred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (deferred therapy)
Trial: 25909356
Drug: Grazoprevir 100
RxNorm normalized name: grazoprevir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg/elbasvir 50 mg
Trial: 22814814
Drug: Ambrisentan therapy
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan therapy for 12 weeks
Trial: 9432193
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing Noveon AA1 (10% w/w)
Trial: 9432193
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing Methocel K4M (10% w/w)
Trial: 9432193
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing Carbopol 974P (10% w/w)
Trial: 28540411
Drug: 12‐month Assertive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12‐month Assertive Community Treatment (ACT) as part of integrated care
Trial: 25732262
Drug: VISCODERM Pearls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VISCODERM Pearls (dietary supplement) administered 2 times a day for 4 weeks
Trial: 25732262
Drug: VISCODERM Pearls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VISCODERM Pearls (dietary supplement)
Trial: 22426799
Drug: Tongyan spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongyan spray
Trial: 20032972
Drug: 75% ethanol
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [XS Wipe 75% Ethanol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% ethanol extract of black cohosh containing 1.4 mg of 23‐epi‐26‐deoxyactein
Trial: 20032972
Drug: 75% ethanol
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [XS Wipe 75% Ethanol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% ethanol extract of black cohosh containing 2.8 mg of 23‐epi‐26‐deoxyactein
Trial: 20032972
Drug: 75% ethanol
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [XS Wipe 75% Ethanol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% ethanol extract of black cohosh containing 5.6 mg of 23‐epi‐26‐deoxyactein
Trial: 18338955
Drug: Tamsulosin, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin, 0.4 mg once daily (Group A)
Trial: 18338955
Drug: No alpha(1)-blocker
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alpha(1)-blocker (Group B, control group)
Trial: 15975174
Drug: Isolated soya
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soya protein (ISP) containing 68 mg/d soy isoflavones (genistein, daidzein, equol)
Trial: 1921739
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg oestriol (E3) vaginal suppository, administered twice weekly for 3 weeks, then weekly for 6 months
Trial: 21457883
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 mg cetirizine (CET) and 120 mg pseudoephedrine (PSE)
Trial: 8845685
Drug: Once-daily levobunolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily levobunolol 0.5%
Trial: 8845685
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% once-daily
Trial: 27920515
Drug: ELOM-080 (3×300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELOM-080 (3×300 mg)
Trial: 24285617
Drug: daily acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily acute intermittent hypoxia (dAIH)
Trial: 24285617
Drug: daily normoxia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily normoxia (dSHAM)
Trial: 22717153
Drug: Inulin supplementation
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin supplementation (0.2 g, 0.3 g, 0.4 g, 0.5 g, and 0.6 g from day 4 to 28)
Trial: 20406355
Drug: Rough surface
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough surface with microthread implants (Hexplant)
Trial: 20406355
Drug: Rough-surface implants
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surface implants (TiUnite)
Trial: 20406355
Drug: Hybrid surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid surface implants (Restore)
Trial: 9931168
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antihypertensive drugs
Trial: 9931168
Drug: Endothelium-independent dilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelium-independent dilation with combination treatment
Trial: 7474028
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reminder call (TC) and satisfaction questionnaire
Trial: 2193261
Drug: Topical intravaginal
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intravaginal clindamycin phosphate (0.1%, 1.0%, and 2.0%)
Trial: 2193261
Drug: Topical intravaginal
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intravaginal clindamycin phosphate (1.0%)
Trial: 471856
Drug: Domperidone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (5 mg i.v.)
Trial: 471856
Drug: Domperidone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (5 mg i.v.) with apomorphine (0.25 mg i.v.)